At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
KAE609 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria
In Brief
A Phase 2 clinical trial evaluating KAE609, SoC (Coartem), and 1 other intervention for Uncomplicated Plasmodium Falciparum Malaria. Completed, enrolled 60 participants across 3 sites in 3 countries.
Detailed Summary
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCôte d’Ivoire, Gabon, Kenya
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartJan 2024
Primary CompletionMar 2025
Study CompletionMar 2025
First PostedNov 2025
TodayJul 2026
First PostedNov 19, 2025
Enrollment StartJan 23, 2024
Primary CompletionMar 5, 2025
Study CompletionMar 19, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7 months ago
Interventions
KAE609drug
oral capsules administered in combination with KLU156
SoC (Coartem)drug
Standard of Care
KLU156drug
oral sachet formulation (KAF156+LUM-SDF) administered in combination with cipargamin (KAE609)